Adaptive Biotechnologies Corp ADPT

Rank #2469 · Nasdaq · $4.3B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

15.5

P/E

-18.9

P/B

21.03

ROE

-111.1%

Op. Margin

-133.3%

Debt Ratio

166%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -18.9x, P/B 21.03x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -111.1%. Ranks in the top 93% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 166%. Ranks in the top 56% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 8.1% year over year. Ranks in the top 81% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	$0.0B	$-0.0B	$-0.0B	$-0.2B	-115.7	-16
2020	$0.1B	$-0.0B	$-0.0B	$-0.2B	-89.4	-152
2021	$0.1B	$-0.1B	$-0.1B	$0.7B	-92.1	50
2022	$0.1B	$-0.2B	$-0.1B	$0.6B	-155.3	53
2023	$0.2B	$-0.2B	$-0.2B	$0.5B	-135.4	85
2024	$0.2B	$-0.2B	$-0.2B	$0.3B	-108.0	114
2025	$0.2B	$-0.2B	$-0.2B	$0.2B	-133.3	166